A whole-genome sequence and transcriptome perspective on HER2-positive breast cancers

Area of Science:

• Genomics
• Oncology
• Breast Cancer Research

Background:

• HER2-positive breast cancer is a distinct subtype with available targeted therapies.
• Treatment resistance highlights the heterogeneity and complexity of HER2-positive breast cancers.
• Understanding this heterogeneity is crucial for effective treatment strategies.

Purpose of the Study:

• To perform in-depth genomic characterization of HER2-positive breast tumors.
• To identify and define subgroups within HER2-positive breast cancer based on genomic features.
• To explore the relationship between HER2-positive breast cancer and the broader luminal-basal spectrum.

Main Methods:

• Genomic characterization of 64 HER2-positive breast tumor genomes.
• Analysis of somatic mutations, copy-number changes, and structural variations.
• Subgroup identification based on gene expression data.

Main Results:

• Identification of four distinct subgroups within HER2-positive breast tumors.
• These subgroups exhibit unique genomic features, including mutations and copy-number alterations.
• HER2-positive tumors integrate into the luminal-basal breast cancer spectrum, challenging their distinct classification.

Conclusions:

• HER2-positive breast cancer is more heterogeneous than previously thought, with distinct genomic subgroups.
• The findings suggest HER2-positive breast cancer is part of a continuum with luminal-basal breast cancers.
• A refined ERBB2 amplicon of 106 kb was identified, with amplifications potentially linked to a breakage-fusion-bridge mechanism.